Status:

COMPLETED

The Influence of Coronary Chronic Total Occlusion on Myocardial Perfusion on Computed Tomography

Lead Sponsor:

National Institute of Cardiology, Warsaw, Poland

Conditions:

Coronary Occlusion

Myocardial Ischemia

Eligibility:

All Genders

18+ years

Brief Summary

The COPACABANA study is designed as a single-centre, open, prospective trial aimed to assess the influence of coronary chronic total occlusion (CTO) on downstream myocardial ischemia via the novel com...

Eligibility Criteria

Inclusion

  • delivery of an informed consent and compliance with study protocol
  • persistent angina pectoris (CCS class ≥2) refractory to optimal medical therapy
  • CTO of a major coronary artery (left anterior descending artery, right coronary artery, left circumflex artery) of at least 2.5 mm vessel diameter confirmed by invasive angiography
  • preserved left ventricular ejection fraction (\>50%) on echocardiography or cardiac magnetic resonance with preserved contractility in the CTO territory (normokinesia and/or hypokinesia)

Exclusion

  • unstable angina and/or myocardial infarction
  • prior myocardial infarction within 4 weeks before study enrolment
  • occurrence of myocardial infarction and/or unplanned revascularization between the index procedure and post-procedural CTP study
  • impaired renal function (eGFR ≤45 ml/min/m2)
  • contraindications to antiplatelet therapy and/or heparin
  • other contraindications to CTP (pregnancy, allergy to contrast media or pharmacologic stress agents, tachyarrhythmia, claustrophobia)

Key Trial Info

Start Date :

February 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2022

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT04465526

Start Date

February 1 2020

End Date

July 1 2022

Last Update

February 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Institute of Cardiology

Warsaw, Poland, 04-628